NCT00646139View on ClinicalTrials.gov

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

March 31, 2009

Conditions
LymphomaLymphoproliferative DisorderSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Src kinase inhibitor KX2-391

OTHER

immunoenzyme technique

OTHER

pharmacological study

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00646139 - KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment | Biotech Hunter | Biotech Hunter